Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein is Inhibited by Zinc in Alzheimer's Disease

Cell

Volumn 142, Issue 6, 2010, Pages 857-867

  Duce, James A ^a   Tsatsanis, Andrew ^a   Cater, Michael A ^a   James, Simon A ^a   Robb, Elysia ^a   Wikhe, Krutika ^a   Leong, Su Ling ^a,b   Perez, Keyla ^a,b   Johanssen, Timothy ^b   Greenough, Mark A ^a   Cho, Hyun Hee ^c   Galatis, Denise ^a   Moir, Robert D ^c   Masters, Colin L ^a   McLean, Catriona ^d   Tanzi, Rudolph E ^c   Cappai, Roberto ^a,b   Barnham, Kevin J ^a,b   Ciccotosto, Giuseppe D ^a,b   Rogers, Jack T ^b,c   Bush, Ashley I ^a   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ALFRED HOSPITAL   (Australia)

Author keywords

Cellbio; Humdisease; Molneuro

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CERULOPLASMIN; IRON; TRANSFERRIN; ZINC;

ALZHEIMER DISEASE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NEOCORTEX; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; METABOLISM; PATHOLOGY; SEQUENCE ALIGNMENT;

MUS;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL LINE; CERULOPLASMIN; HUMANS; IRON; MICE; SEQUENCE ALIGNMENT; ZINC;

EID: 77956647381     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2010.08.014     Document Type: Article

References (64)

1. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59:43-55.
2. Bakker G.R., Boyer R.F. Iron incorporation into apoferritin. The role of apoferritin as a ferroxidase. J. Biol. Chem. 1986, 261:13182-13185.
3. Bartzokis G., Tishler T.A. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell. Mol. Biol. (Noisy-le-grand) 2000, 46:821-833.
4. Bartzokis G., Mintz J., Sultzer D., Marx P., Herzberg J.S., Phelan C.K., Marder S.R. In vivo MR evaluation of age-related increases in brain iron. AJNR Am. J. Neuroradiol. 1994, 15:1129-1138.
5. Bartzokis G., Sultzer D., Mintz J., Holt L.E., Marx P., Phelan C.K., Marder S.R. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol. Psychiatry 1994, 35:480-487.
6. Bodovitz S., Falduto M.T., Frail D.E., Klein W.L. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J. Neurochem. 1995, 64:307-315.
7. Bush A.I., Pettingell W.H., Multhaup G., d Paradis M., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L., Tanzi R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994, 265:1464-1467.
8. Cherny R.A., Legg J.T., McLean C.A., Fairlie D., Huang X., Atwood C.S., Beyreuther K., Tanzi R.E., Masters C.L., Bush A.I. Aqueous dissolution of Alzheimer's disease Aß amyloid deposits by biometal depletion. J. Biol. Chem. 1999, 274:23223-23228.
9. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
10. Chinnery P.F., Crompton D.E., Birchall D., Jackson M.J., Coulthard A., Lombes A., Quinn N., Wills A., Fletcher N., Mottershead J.P., et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007, 130:110-119.
11. Cras P., Kawai M., Lowery D., Gonzalez-DeWhitt P., Greenberg B., Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc. Natl. Acad. Sci. USA 1991, 88:7552-7556.
12. De Domenico I., Ward D.M., di Patti M.C., Jeong S.Y., David S., Musci G., Kaplan J. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J. 2007, 26:2823-2831.
13. De Domenico I., Nemeth E., Nelson J.M., Phillips J.D., Ajioka R.S., Kay M.S., Kushner J.P., Ganz T., Ward D.M., Kaplan J. The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab. 2008, 8:146-156.
14. Ding B., Chen K.M., Ling H.W., Sun F., Li X., Wan T., Chai W.M., Zhang H., Zhan Y., Guan Y.J. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J. Magn. Reson. Imaging 2009, 29:793-798.
15. Dong J., Atwood C.S., Anderson V.E., Siedlak S.L., Smith M.A., Perry G., Carey P.R. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 2003, 42:2768-2773.
16. El Tannir El Tayara N., Delatour B., Le Cudennec C., Guegan M., Volk A., Dhenain M. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2006, 22:199-208.
17. Falangola M.F., Lee S.P., Nixon R.A., Duff K., Helpern J.A. Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem. Res. 2005, 30:201-205.
18. Faux N.G., Ritchie C.W., Gunn A., Rembach A., Tsatsanis A., Bedo J., Harrison J., Lannfelt L., Blennow K., Zetterberg H., et al. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J. Alzheimers Dis. 2010, 20:509-516.
19. Furukawa K., Sopher B.L., Rydel R.E., Begley J.G., Pham D.G., Martin G.M., Fox M., Mattson M.P. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 1996, 67:1882-1896.
20. Gonzalez-Cuyar L.F., Perry G., Miyajima H., Atwood C.S., Riveros-Angel M., Lyons P.F., Siedlak S.L., Smith M.A., Castellani R.J. Redox active iron accumulation in aceruloplasminemia. Neuropathology 2008, 28:466-471.
21. Gray C.W., Patel A.J. Induction of beta-amyloid precursor protein isoform mRNAs by bFGF in astrocytes. Neuroreport 1993, 4:811-814.
22. Grundke-Iqbal I., Fleming J., Tung Y.C., Lassmann H., Iqbal K., Joshi J.G. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. 1990, 81:105-110.
23. Gutierrez J.A., Yu J., Rivera S., Wessling-Resnick M. Functional expression cloning and characterization of SFT, a stimulator of Fe transport. J. Cell Biol. 1997, 139:895-905.
24. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 1958, 3:41-51.
25. Hao Q., Maret W. Imbalance between pro-oxidant and pro-antioxidant functions of zinc in disease. J. Alzheimers Dis. 2005, 8:161-170.
26. Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., MacGillivray R.T., Gitlin J.D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. USA 1995, 92:2539-2543.
27. Honda K., Smith M.A., Zhu X., Baus D., Merrick W.C., Tartakoff A.M., Hattier T., Harris P.L., Siedlak S.L., Fujioka H., et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J. Biol. Chem. 2005, 280:20978-20986.
28. Jack C.R., Wengenack T.M., Reyes D.A., Garwood M., Curran G.L., Borowski B.J., Lin J., Preboske G.M., Holasek S.S., Adriany G., et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 2005, 25:10041-10048.
29. Jeong S.Y., David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 2003, 278:27144-27148.
30. Jeong S.Y., David S. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J. Neurosci. 2006, 26:9810-9819.
31. Klausner R.D., Rouault T.A., Harford J.B. Regulating the fate of mRNA: The control of cellular iron metabolism. Cell 1993, 72:19-28.
32. Klomp L.W., Farhangrazi Z.S., Dugan L.L., Gitlin J.D. Ceruloplasmin gene expression in the murine central nervous system. J. Clin. Invest. 1996, 98:207-215.
33. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008, 7:779-786.
34. Lawson D.M., Artymiuk P.J., Yewdall S.J., Smith J.M., Livingstone J.C., Treffry A., Luzzago A., Levi S., Arosio P., Cesareni G., et al. Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature 1991, 349:541-544.
35. Lawson D.M., Treffry A., Artymiuk P.J., Harrison P.M., Yewdall S.J., Luzzago A., Cesareni G., Levi S., Arosio P. Identification of the ferroxidase centre in ferritin. FEBS Lett. 1989, 254:207-210.
36. Lee J.-Y., Cole T.B., Palmiter R.D., Suh S.W., Koh J.-Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99:7705-7710.
37. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 1998, 158:47-52.
38. Mantovan M.C., Martinuzzi A., Squarzanti F., Bolla A., Silvestri I., Liessi G., Macchi C., Ruzza G., Trevisan C.P., Angelini C. Exploring mental status in Friedreich's ataxia: a combined neuropsychological, behavioral and neuroimaging study. Eur. J. Neurol. 2006, 13:827-835.
39. Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I., Rydel R.E. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein. Neuron 1993, 10:243-254.
40. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., White A.R., Beyreuther K., Masters C.L., Bush A.I., Li Q.X. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 2002, 277:44670-44676.
41. Meloni G., Sonois V., Delaine T., Guilloreau L., Gillet A., Teissie J., Faller P., Vasak M. Metal swap between Zn7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. Nat. Chem. Biol. 2008, 4:366-372.
42. Miller L.M., Wang Q., Telivala T.P., Smith R.J., Lanzirotti A., Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J. Struct. Biol. 2006, 155:30-37.
43. Mita S., Schon E.A., Herbert J. Widespread expression of amyloid beta-protein precursor gene in rat brain. Am. J. Pathol. 1989, 134:1253-1261.
44. Ninomiya H., Roch J.M., Sundsmo M.P., Otero D.A., Saitoh T. Amino acid sequence RERMS represents the active domain of amyloid beta/A4 protein precursor that promotes fibroblast growth. J. Cell Biol. 1993, 121:879-886.
45. 2. J. Biol. Chem. 2002, 277:40302-40308.
46. Osaki S. Kinetic studies of ferrous ion oxidation with crystalline human ferroxidase (ceruloplasmin). J. Biol. Chem. 1966, 241:5053-5059.
47. Patel B.N., Dunn R.J., Jeong S.Y., Zhu Q., Julien J.P., David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J. Neurosci. 2002, 22:6578-6586.
48. Qian Z.M., Chang Y.Z., Leung G., Du J.R., Zhu L., Wang Q., Niu L., Xu Y.J., Yang L., Ho K.P., et al. Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart. Biochim. Biophys. Acta 2007, 1772:527-532.
49. Religa D., Strozyk D., Cherny R.A., Volitakis I., Haroutunian V., Winblad B., Naslund J., Bush A.I. Elevated cortical zinc in Alzheimer disease. Neurology 2006, 67:69-75.
50. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003, 60:1685-1691.
51. Robinson S.R., Noone D.F., Kril J., Halliday G.M. Most amyloid plaques contain ferritin-rich cells. Alzheimer's Res. 1995, 1:191-196.
52. Rogers J.T., Randall J.D., Cahill C.M., Eder P.S., Huang X., Gunshin H., Leiter L., McPhee J., Sarang S.S., Utsuki T., et al. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002, 277:45518-45528.
53. Rohan de Silva H.A., Jen A., Wickenden C., Jen L.S., Wilkinson S.L., Patel A.J. Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes. Brain Res. Mol. Brain Res. 1997, 47:147-156.
54. Rossjohn J., Cappai R., Feil S.C., Henry A., McKinstry W.J., Galatis D., Hesse L., Multhaup G., Beyreuther K., Masters C.L., et al. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol. 1999, 6:327-331.
55. Smith M.A., Harris P.L., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 1997, 94:9866-9868.
56. Suh S.W., Jensen K.B., Jensen M.S., Silva D.S., Kesslak P.J., Danscher G., Frederickson C.J. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 2000, 852:274-278.
57. Takahashi M., Dore S., Ferris C.D., Tomita T., Sawa A., Wolosker H., Borchelt D.R., Iwatsubo T., Kim S.H., Thinakaran G., et al. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron 2000, 28:461-473.
58. Toussaint L., Bertrand L., Hue L., Crichton R.R., Declercq J.P. High-resolution X-ray structures of human apoferritin H-chain mutants correlated with their activity and metal-binding sites. J. Mol. Biol. 2007, 365:440-452.
59. Uchida Y., Takio K., Titani K., Ihara Y., Tomonaga M. The growth-inhibitory factor that is deficient in the Alzheimer's disease brain is a 68-amino acid metallothionein-like protein. Neuron 1991, 7:337-347.
60. Visser C.C., Voorwinden L.H., Crommelin D.J., Danhof M., de Boer A.G. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm. Res. 2004, 21:761-769.
61. Wang Y., Ha Y. The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. Mol. Cell 2004, 15:343-353.
62. Yamamoto A., Shin R.W., Hasegawa K., Naiki H., Sato H., Yoshimasu F., Kitamoto T. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J. Neurochem. 2002, 82:1137-1147.
63. Yang X., Chen-Barrett Y., Arosio P., Chasteen N.D. Reaction paths of iron oxidation and hydrolysis in horse spleen and recombinant human ferritins. Biochemistry 1998, 37:9743-9750.
64. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.